TY - JOUR
T1 - Omega-3 fatty acids and coronary heart disease risk
T2 - Clinical and mechanistic perspectives
AU - Harris, William S.
AU - Miller, Michael
AU - Tighe, Ann P.
AU - Davidson, Michael H.
AU - Schaefer, Ernst J.
N1 - Funding Information:
Dr. Harris is a consultant to the Monsanto Company and Reliant Pharmaceuticals, has received research grants from each, and has served as a speaker for CME programs sponsored by the latter. Dr. Tighe is an employee of Scientiae, which provides editorial assistance to Reliant Pharmaceuticals. Dr. Miller has received grant funding from AstraZeneca, Merck, Schering Plough, and Pfizer, and honoraria from AstraZeneca, Merck, Schering Plough, Pfizer, and Reliant. Dr. Davidson has received grant/research support or honoraria, or served as a consultant or on the speakers’ bureau, for the following companies in the past three years: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Kos Pharmaceuticals, and Reliant. Dr. Schaefer is a consultant, or an advisor, or has received research grants within the past two years, from the following companies: Abbott, AstraZeneca, Merck, Merck-Schering, Pfizer, Reliant, Schering, and Unilever Corporations.
PY - 2008/3
Y1 - 2008/3
N2 - The most common omega-3 fatty acids contain 18-22 carbons and a signature double bond at the third position from the methyl (or n, or omega) end of the molecule. These fatty acids must be obtained in the diet as they cannot be synthesized by vertebrates. They include the plant-derived α-linolenic acid (ALA, 18:3n-3), and the fish-oil-derived eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). Normally, very little ALA is converted to EPA, and even less to DHA, and therefore direct intake of the latter two is optimal. EPA and DHA and their metabolites have important biologic functions, including effects on membranes, eicosanoid metabolism, and gene transcription. Studies indicate that the use of fish oil is associated with coronary heart disease risk reduction. A number of mechanisms may be responsible for such effects. These include prevention of arrhythmias as well as lowering heart rate and blood pressure, decreasing platelet aggregation, and lowering triglyceride levels. The latter is accomplished by decreasing the production of hepatic triglycerides and increasing the clearance of plasma triglycerides. Our focus is to review the potential mechanisms by which these fatty acids reduce cardiovascular disease risk.
AB - The most common omega-3 fatty acids contain 18-22 carbons and a signature double bond at the third position from the methyl (or n, or omega) end of the molecule. These fatty acids must be obtained in the diet as they cannot be synthesized by vertebrates. They include the plant-derived α-linolenic acid (ALA, 18:3n-3), and the fish-oil-derived eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). Normally, very little ALA is converted to EPA, and even less to DHA, and therefore direct intake of the latter two is optimal. EPA and DHA and their metabolites have important biologic functions, including effects on membranes, eicosanoid metabolism, and gene transcription. Studies indicate that the use of fish oil is associated with coronary heart disease risk reduction. A number of mechanisms may be responsible for such effects. These include prevention of arrhythmias as well as lowering heart rate and blood pressure, decreasing platelet aggregation, and lowering triglyceride levels. The latter is accomplished by decreasing the production of hepatic triglycerides and increasing the clearance of plasma triglycerides. Our focus is to review the potential mechanisms by which these fatty acids reduce cardiovascular disease risk.
KW - Arrhythmia
KW - Coronary heart disease
KW - Omega-3 fatty acids
KW - Platelet aggregation
KW - Triglyceride
UR - http://www.scopus.com/inward/record.url?scp=39649111988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39649111988&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2007.11.008
DO - 10.1016/j.atherosclerosis.2007.11.008
M3 - Review article
C2 - 18160071
AN - SCOPUS:39649111988
SN - 0021-9150
VL - 197
SP - 12
EP - 24
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -